SCHEMBL6207779

SCHEMBL6207779

[CH2]CCOc1ccc(-c2nnc(-c3cccc(-c4ccccc4)c3)o2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 15/20 0.57
RAB9A P51151 14/20 0.57
SMN1; SMN2 Q16637 12/20 0.57
KDM4E B2RXH2 9/20 0.57
ALDH1A1 P00352 9/20 0.57
HPGD P15428 8/20 0.57
TP53 P04637 6/20 0.57
MAPT P10636 9/20 0.48
TSHR P16473 8/20 0.48
LMNA P02545 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HSD17B10 Q99714 6/20 0.48
CASP3 P42574 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
SENP6 Q9GZR1 1/20 0.48
POLB P06746 1/20 0.47
MECP2 P51608 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6185875 0.84 RAB9A (0.57) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL5640855 0.82 LSS (0.66) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL72837 0.79 LSS (0.56) NPC1RAB9AALDH1A1
SCHEMBL12306750 0.79 NPC1 (0.74) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL10493895 0.79 NPC1 (0.74) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL12306757 0.77 NPC1 (0.77) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL6205204 0.75 QPCT (0.54) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL14378791 0.75 NPC1 (0.81) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL8539823 0.74 LTA4H (0.57) ALDH1A1
SCHEMBL5640169 0.74 LSS (0.75) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1505968-A1 MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES ELI LILLY AND COMPANY (US) 2005-02-16 EP disclosed
WO-2003097047-A1 MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES ELI LILLY AND COMPANY (US) 2003-11-27 WO disclosed